Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls

Round 1

Reviewer 1 Report

This report on Trop-2 therapy in Metastatic Triple négative Breast Cancer is not a reserch article; it is a communication to  highlight the importance of regulatory issues on the clinical use of a new therapeutic agent . it is like a review article about  a glycoproteine Trop-2 and  new therapy Sacituzumab govitecan

minor precisions:

there is no introduction!

what is ADC: explain all abbreviations when useful

join the lines 67-68

Author Response

We provide a point-by point response to the reviewer's comments and we inserted a grafical abstract as requested by the Assistant Editor (Ms Alina Cenan).

We inserted the introduction at page 6 as requested and new references (1-6).

We explained the meaning of ADC and we explained all the others abbreviations as requested.

We joined the lines 67-68 as requested.

 

 

Reviewer 2 Report

I would like to thank the authors for this interesting communication, which has might have a clinical impact. The process of any drug approval is very lengthy, which is not in the benefit of the oncologic patients. 

I would require that the authors revise the language and the grammar of the article. Also, some abbreviations need to be spelled out. Some examples are highlighted in the attached document. 

Comments for author File: Comments.pdf

Author Response

We provide a point-by point response to the reviewer's comments and we inserted a grafical abstract as requested by the Assistant Editor (Ms Alina Cenan).

We thank the reviewer for the positive comment.

We  corrected the language and the typos of the article. 

Abbreviations have been spelled out (they have been highlighted in red).

 

This manuscript is a resubmission of an earlier submission. The following is a list of the peer review reports and author responses from that submission.